NASDAQ:FULC Fulcrum Therapeutics Q3 2026 Earnings Date & Estimates $3.71 -0.06 (-1.59%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$3.72 +0.00 (+0.13%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Fulcrum Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Fulcrum Therapeutics in Q3 2026Fulcrum Therapeutics is expected to post earnings of -$0.0745 per share. In the same quarter a year earlier Fulcrum Therapeutics reported -$0.31 per share. Fulcrum Therapeutics last reported on July 30, 2026, posting -$0.34 per share and missing the -$0.2433 consensus estimate. Fulcrum Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.0745Prior-Year EPS-$0.31Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.34 (Missed by -$0.0967)EPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Fulcrum Therapeutics Q3 2026 Earnings FAQ When does Fulcrum Therapeutics report Q3 2026 earnings? Fulcrum Therapeutics (NASDAQ:FULC) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Fulcrum Therapeutics' Q3 2026 earnings call? Fulcrum Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 7:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Fulcrum Therapeutics? Analysts expect Fulcrum Therapeutics to post earnings of -$0.0745 per share for Q3 2026. Fulcrum Therapeutics Earnings HeadlinesFulcrum Therapeutics (FULC) Expected to Release Earnings on ThursdayOctober 22, 2026 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Now Rated "Reduce" by Wall Street AnalystsOctober 21, 2026 | americanbankingnews.comDollar Reset – Are You Prepared?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 1 at 1:00 AM | Porter & Company (Ad)Kaplan Fox is Investigating Whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Made Misleading Statements to InvestorsOctober 10, 2026 | theglobeandmail.comKaplan Fox Alerts Investors: Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is Under Investigation for Potential Securities Law ViolationsOctober 5, 2026 | theglobeandmail.comFulcrum Therapeutics consensus price target raised 11.22% to $7.75October 2, 2026 | msn.comSee More Fulcrum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email. Email Address About Fulcrum TherapeuticsFulcrum Therapeutics (NASDAQ:FULC) is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases. The company’s research approach is based on selectively modulating gene expression to address the underlying biology of disease rather than targeting individual symptoms. Fulcrum’s lead investigational program is losmapimod, an oral small-molecule therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive genetic muscle disorder. The company has also researched therapies for other diseases, including sickle cell disease, using compounds intended to increase fetal hemoglobin production. Founded in 2016 and headquartered in Waltham, Massachusetts, Fulcrum serves the global biopharmaceutical market through its research and clinical-development activities. The company’s programs are directed toward patients with serious conditions for which treatment options may be limited, and its development efforts are supported by collaborations and regulatory interactions where applicable.View Fulcrum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatEli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation ResetMarketBeat Week in Review – 10/26 - 10/30DoorDash's $17 Billion Bet on Instacart Faces a Long Regulatory Road AheadAmazon's Record Margins Couldn't Stop the Sell-Off—Here's Why Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
